Rydapt loe and patent expiration?

Rydapt (midostaurin) LOE and patent expiry depend on the country and on multiple patent families (composition, use, formulation, etc.). There isn’t a single universal date. In the US and EU, there are several patents around midostaurin and its uses, and regulatory data/exclusivity can also affect when a generic could enter.

What I can do for you:
- If you tell me the country (US, EU, etc.) and whether you want US-only or global, I can summarize the current status (patent expiration dates by family, and any applicable regulatory exclusivity).
- I can guide you to where to look now (official sources) and how to interpret the results.

How to check yourself (quick guide):
- US: FDA’s Orange Book lists patents and exclusivities tied to a drug. Look up midostaurin or Rydapt and review the “Patents” and “Exclusivities” sections. Also check the USPTO Patent Full-Text database for the exact patent numbers and term extensions (if any).
- Europe: European Patent Office (Espacenet) for individual patent families covering midostaurin and for the EU market protection dates.
- Other major markets: check national patent offices or the respective national/regulatory databases; there are often similar patent and exclusivity listings.
- Be mindful of:
- Different patent families (composition of matter vs. method-of-use vs. formulation) with different expiry dates.
- Patent term extensions or regulatory delays that can push expiry beyond the base term.
- Possible market exclusivities (data exclusivity, pediatric exclusivity) that can affect timing of generic entry.

If you want, I can look up the current US and EU status for midostaurin and summarize the exact expiry dates and active patents. Just tell me the country(ies) you care about.